Cabaletta Bio Inc
NASDAQ:CABA
Intrinsic Value
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CABA.
Cabaletta Bio Inc's market capitalization is 582.5m USD.
CABA stock price is 12.18 USD.
CABA.
CABA. Open DCF Valuation
CABA. Open Relative Valuation
CABA has upside potential of 186% compared to the average analyst price target.
Open Wall St Estimates
CABA has negative Free Cash Flow for the last twelve months.
CABA's ROE (Return on Equity) has decreased in the last 3 years from -30% to -40%, and is approaching profitability.
CABA has negative Operating Income for the last twelve months.
CABA has negative Net Income for the last twelve months.
CABA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 208% to -942%, and is approaching profitability.
CABA's ROE (Return on Equity) for the past 12 months is negative and is equal to -40%.
CABA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -942%.
CABA has negative three-year average ROE (Return on Equity): -43%. The company is not efficient at transforming stockholders' equity into net income.
CABA has negative three-year average ROIC (Return on Invested Capital): -1 441%. The company is not efficient at using invested capital to generate operating income.
CABA's short-term assets (244m USD) exceed its short-term liabilties (16m USD).
CABA's long-term assets (254m USD) exceed its long-term liabilties (17m USD).
CABA's D/E (Debt to Equity) is very low and is equal to 0.
CABA's Altman Z-Score is very high and is equal to 35.
Fundamental Analysis
Cabaletta Bio Inc
Balance Sheet Decomposition
Cabaletta Bio Inc
| Current Assets | 244.5m |
| Cash & Short-Term Investments | 241.2m |
| Other Current Assets | 3.2m |
| Non-Current Assets | 9.2m |
| PP&E | 7.5m |
| Other Non-Current Assets | 1.7m |
| Current Liabilities | 16m |
| Accounts Payable | 4.5m |
| Accrued Liabilities | 8.8m |
| Other Current Liabilities | 2.7m |
| Non-Current Liabilities | 1.5m |
| Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Cabaletta Bio Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-74.7m
USD
|
|
Operating Income
|
-74.7m
USD
|
|
Other Expenses
|
7m
USD
|
|
Net Income
|
-67.7m
USD
|
Free Cash Flow Analysis
Cabaletta Bio Inc
CABA Profitability Score
Profitability Due Diligence
Cabaletta Bio Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Cabaletta Bio Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
CABA Solvency Score
Solvency Due Diligence
Cabaletta Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Cabaletta Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CABA Price Targets Summary
Cabaletta Bio Inc
According to Wall Street analysts, the average 1-year price target for
CABA
is 34.79 USD
with a low forecast of 25.25 USD and a high forecast of 52.5 USD.
Ownership
CABA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CABA Price
Cabaletta Bio Inc
| Average Annual Return | 25.74% |
| Standard Deviation of Annual Returns | 88.83% |
| Max Drawdown | -97% |
| Market Capitalization | 582.5m USD |
| Shares Outstanding | 48 241 600 |
| Percentage of Shares Shorted | 19.68% |
Company Profile
Cabaletta Bio Inc
Country
Industry
Market Cap
Dividend Yield
Description
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 53 full-time employees. The company went IPO on 2019-10-25. The firm is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The firm's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The firm has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
You don't have any saved screeners yet
